AU2001247474A1 - Compounds for the treatment of psychiatric or substance abuse disorders - Google Patents

Compounds for the treatment of psychiatric or substance abuse disorders

Info

Publication number
AU2001247474A1
AU2001247474A1 AU2001247474A AU4747401A AU2001247474A1 AU 2001247474 A1 AU2001247474 A1 AU 2001247474A1 AU 2001247474 A AU2001247474 A AU 2001247474A AU 4747401 A AU4747401 A AU 4747401A AU 2001247474 A1 AU2001247474 A1 AU 2001247474A1
Authority
AU
Australia
Prior art keywords
psychiatric
compounds
treatment
substance abuse
abuse disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001247474A
Inventor
Perry F. Renshaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mclean Hospital Corp
Original Assignee
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclean Hospital Corp filed Critical Mclean Hospital Corp
Publication of AU2001247474A1 publication Critical patent/AU2001247474A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
AU2001247474A 2000-03-16 2001-03-15 Compounds for the treatment of psychiatric or substance abuse disorders Abandoned AU2001247474A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18972800P 2000-03-16 2000-03-16
US18972700P 2000-03-16 2000-03-16
US18981100P 2000-03-16 2000-03-16
US60189727 2000-03-16
US60189811 2000-03-16
US60189728 2000-03-16
PCT/US2001/008398 WO2001068104A1 (en) 2000-03-16 2001-03-15 Compounds for the treatment of psychiatric or substance abuse disorders

Publications (1)

Publication Number Publication Date
AU2001247474A1 true AU2001247474A1 (en) 2001-09-24

Family

ID=27392624

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001247474A Abandoned AU2001247474A1 (en) 2000-03-16 2001-03-15 Compounds for the treatment of psychiatric or substance abuse disorders

Country Status (5)

Country Link
US (3) US8030294B2 (en)
EP (1) EP1274444B1 (en)
AU (1) AU2001247474A1 (en)
ES (1) ES2425114T3 (en)
WO (1) WO2001068104A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
ES2170649B1 (en) * 2000-03-29 2003-06-16 Ferrer Int USE OF CDP-HILL IN THE TREATMENT OF ALCOHOLIC ABSTINENCE.
WO2002066672A2 (en) * 2001-01-16 2002-08-29 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
US20050283053A1 (en) * 2002-01-30 2005-12-22 Decharms Richard C Methods for physiological monitoring, training, exercise and regulation
WO2002061457A2 (en) 2001-01-30 2002-08-08 Decharms R Christopher Methods for physiological monitoring, training, exercise and regulation
US20020103429A1 (en) * 2001-01-30 2002-08-01 Decharms R. Christopher Methods for physiological monitoring, training, exercise and regulation
US20050177200A1 (en) * 2002-05-03 2005-08-11 George Mark S. Method, apparatus and system for determining effects and optimizing parameters of vagus nerve stimulation
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
WO2003101402A2 (en) * 2002-06-04 2003-12-11 Avicena Group, Inc. Methods of treating cognitive dysfunction by modulating brain energy metabolism
US20040092809A1 (en) * 2002-07-26 2004-05-13 Neurion Inc. Methods for measurement and analysis of brain activity
BR0316054A (en) * 2002-11-08 2005-09-20 Mclean Hospital Corp Tobacco addiction and deprivation treatment compounds
RU2366428C2 (en) * 2002-12-20 2009-09-10 Дзе Маклин Хоспитал Корпорейшн Compounds used for sleep/wakefulness cycle normalisation
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
DK1617832T3 (en) 2003-04-29 2008-07-07 Orexigen Therapeutics Inc Preparations for the effect of weight loss
US8524665B2 (en) * 2003-05-13 2013-09-03 The Mclean Hospital Corporation Use of secretin in treatments of disorders associated with the amygdala
US20050033154A1 (en) * 2003-06-03 2005-02-10 Decharms Richard Christopher Methods for measurement of magnetic resonance signal perturbations
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
EP1727554A4 (en) * 2003-10-08 2009-09-30 Mclean Hospital Corp Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005070461A2 (en) * 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
EP1765075A4 (en) * 2004-06-10 2010-11-10 Mclean Hospital Corp Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
US20090215714A1 (en) * 2004-06-10 2009-08-27 Perry Renshaw Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
US7860552B2 (en) * 2004-10-01 2010-12-28 The Mclean Hospital Corporation CNS assay for prediction of therapeutic efficacy for neuropathic pain and other functional illnesses
WO2006055582A2 (en) * 2004-11-15 2006-05-26 Christopher Decharms Stimulation of neural tissue with light
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007059762A1 (en) * 2005-11-25 2007-05-31 Gisela Susilo Combination preparations containing physiological cell membrane constituents including phosphatidylserine, choline and a pyrimidine nucleoside/nucleotide
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20190042766A (en) 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
EP2303025A4 (en) * 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Methods for treating visceral fat conditions
US20100041620A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods for improving frontal brain bioenergetic metabolism
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
BR112012016783A2 (en) * 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "Uses of the naltrexone compound or pharmaceutically acceptable salt thereof to bupropion or pharmaceutically acceptable salt thereof or composition thereof and methods for providing therapy"
US20130281410A1 (en) * 2010-05-13 2013-10-24 University Of Utah Research Foundation Methods for the treatment of psychiatric disorders
WO2012048243A2 (en) * 2010-10-08 2012-04-12 University Of Utah Research Foundation Depression disorder therapeutics with creatine analogs
PE20141198A1 (en) 2011-09-19 2014-10-05 Orexo Ab NEW PHARMACEUTICAL COMPOSITION RESISTANT TO ABUSE FOR THE TREATMENT OF OPIOID DEPENDENCE
RU2495670C2 (en) * 2011-12-30 2013-10-20 Андрей Владимирович Михайлов Method for addictive behaviour correction
KR20200035501A (en) 2012-06-06 2020-04-03 오렉시젠 세러퓨틱스 인크. Methods of treating overweight and obesity
WO2014014960A1 (en) * 2012-07-16 2014-01-23 Dignity Health Treating of epilepsy and alcohol addiction with creatine
CN106102765A (en) 2014-02-07 2016-11-09 犹他大学研究基金会 The combination of creatine, omega-3 fatty acid and citicoline

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873698A (en) 1973-10-10 1975-03-25 Addiction Research And Treatme Method of combatting morphine addiction and toxification
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4115576A (en) * 1974-04-02 1978-09-19 Penn Nathar W Compositions and method of employing the same for inhibiting alcohol intoxication
US4027017A (en) * 1974-07-16 1977-05-31 Chugai Seiyaku Kabushiki Kaisha Method of treating alcoholism
US4346084A (en) 1980-02-29 1982-08-24 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lithium and choline
US4569929A (en) 1980-02-29 1986-02-11 Massachusetts Institute Of Technology Cytidyl diphosphocholine-drug composition
IT1207106B (en) 1980-04-18 1989-05-17 Made Italiana Srl Ora Searle I PHARMACEUTICAL PREPARATION CONTAINING CITIDIN DISFOFOCOLINA ABSORBABLE ORALLY
EP0263533A3 (en) 1983-03-01 1990-05-30 C.R.C. Compagnia di Ricerca Chimica S.p.A. A method for preparing the cytidine monophosphate of 5-acetamido-3,5-dideoxy-d-glycero-d-galactononulosaminic acid
DE3400276A1 (en) 1984-01-05 1985-07-18 Ferrer Internacional S.A., Barcelona Use of CDP-choline for the treatment of neurological disturbances
DE3570441D1 (en) 1985-01-24 1989-06-29 Neopharmed Spa Acylated derivatives of cytidine-diphosphate-choline, process for their preparation and their therapeutic use
IT1200589B (en) 1985-02-14 1989-01-27 Gibipharma Spa NATURAL DERIVATIVES PHARMAGOLOGICAL ACTIVITY
IT1201474B (en) 1985-10-01 1989-02-02 Vincenzo Zappia MACROMOLECULARIZED DERIVATIVES OF CDP-COLINA, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
JPH0828589B2 (en) 1987-02-25 1996-03-21 日本電気株式会社 LSI cooling structure
JPS63208524A (en) 1987-02-25 1988-08-30 Nippon Oil & Fats Co Ltd Sleep rhythm improver
US7173017B1 (en) * 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
AU2789989A (en) 1987-10-28 1989-05-23 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof
IT1219667B (en) 1988-06-21 1990-05-24 Polifarma Spa USE OF URIDINE IN THE PHARMACOLOGICAL TREATMENT OF DISORDERS DUE TO ALTERATED DOPAMINERGIC BALANCE
US4999382A (en) 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US5179126A (en) 1988-10-26 1993-01-12 Massachusettes Institute Of Technology Compositions for treating tobacco withdrawl symtoms and methods for their use
RU2003332C1 (en) 1989-06-09 1993-11-30 Борис Витальевич Страдомский Agent for treatment depression
US5069895A (en) 1989-11-09 1991-12-03 Diamond Ivan F Methods for the treatment of alcohol intoxication and dependence
US5635486A (en) 1990-05-11 1997-06-03 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Ophthalmic composition comprising a sleep adjusting substance
JPH0418034A (en) 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd Eye drop composition
WO1992021339A1 (en) 1991-05-29 1992-12-10 Abbott Laboratories Isoxazole and isothiazole compounds that enhance cognitive function
GB9200293D0 (en) 1992-01-08 1992-02-26 Wyeth John & Brother Ltd Piperazine derivatives
US5278176A (en) 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
GB9303157D0 (en) 1993-02-17 1993-03-31 Scotia Holdings Plc Treatment of a group of related disorders
JPH0710823A (en) 1993-06-22 1995-01-13 Teijin Ltd N-3 unsaturated fatty acid derivative and pharmaceutical composition containing the derivative
JP2500372B2 (en) 1993-11-10 1996-05-29 科学技術庁航空宇宙技術研究所長 Tensile impact test equipment
US5472958A (en) 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
DE69535104T2 (en) 1994-11-08 2007-02-08 Avicena Group, Inc., Cambridge USE OF CREATINE OR CREATINANOLOGISTS FOR THE TREATMENT OF HUNTINGTON CHOREA, MORBUS PARKINSON AND AMYOTROPHES LATERAL SCLEROSIS
JPH08183737A (en) 1994-12-28 1996-07-16 Advance Co Ltd Alcohol absorption inhibitor
US5691365A (en) 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
WO1998006855A1 (en) * 1996-08-16 1998-02-19 The Texas A & M University System Compositions and methods for delivery of nucleic acids to hepatocytes
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
SK285210B6 (en) 1996-10-11 2006-09-07 Scarista Limited A pharmaceutical preparation for the treatment of schizophrenia and use of an oil comprising eicosapentaenoic or stearidonic acid, or combination thereof in the manufacture of the medicament
GB9623859D0 (en) 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US6852870B2 (en) 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US5977174A (en) 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
WO1999029316A1 (en) 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US20060128671A1 (en) 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
US6132724A (en) 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
EP2329829B1 (en) 1998-07-31 2014-04-16 Massachusetts Institute of Technology Use of uridine in combination with choline for the treatment of neurological disorders
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
HN1999000146A (en) 1998-09-21 2000-11-11 Pfizer Prod Inc PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PARKINSON'S DISEASE, ADHD AND MICROADENOMAS.
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
DE19929995B4 (en) 1999-06-30 2004-06-03 Skw Trostberg Ag Use of creatine and / or creatine derivatives for the treatment of mental disorders in women
AU8028600A (en) 1999-10-20 2001-04-30 Eliezer Rapaport Methods, pharmaceutical and therapeutic compositions for administering adenosine
US6258794B1 (en) 1999-12-14 2001-07-10 The Mclean Hospital Corporation Treatment of mental conditions including depression
WO2001068104A1 (en) 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
ES2170649B1 (en) 2000-03-29 2003-06-16 Ferrer Int USE OF CDP-HILL IN THE TREATMENT OF ALCOHOLIC ABSTINENCE.
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6520921B1 (en) 2000-06-20 2003-02-18 Eastman Kodak Company Method for determining attention deficit hyperactivity disorder (ADHD) medication dosage and for monitoring the effects of (ADHD) medication
US6727231B1 (en) 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
IL139224A (en) 2000-10-23 2009-09-01 David Rutenberg Anti depressant, stress suppressor and mood improver
US20020102211A1 (en) 2000-12-07 2002-08-01 Renshaw Perry F. Use of magnetic resonance imaging in diagnosis of membrane fluidity-related disorders
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
EE05434B1 (en) 2001-04-30 2011-06-15 Trommsdorff Gmbh & Co. Kg Arzneimittel Pharmaceutically active uridine esters
US6541043B2 (en) 2001-08-28 2003-04-01 Dexgen Pharmaceuticals, Inc. Method and synergistic composition for treating attention deficit/hyperactivity disorder
WO2003032914A2 (en) 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
US20030114415A1 (en) 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
US7439264B2 (en) 2002-02-08 2008-10-21 President And Fellows Of Harvard College Therapeutic compounds
AU2003241281A1 (en) 2002-03-27 2003-10-13 The Regents Of The University Of California Synergy of dopamine d2 and adenosine a2 receptors activates pka signaling via beta/gamma dimers
US20030224435A1 (en) 2002-05-16 2003-12-04 Scott Seiwert Detection of abused substances and their metabolites using nucleic acid sensor molecules
US7026301B2 (en) 2002-10-17 2006-04-11 New York University Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
BR0316054A (en) 2002-11-08 2005-09-20 Mclean Hospital Corp Tobacco addiction and deprivation treatment compounds
RU2366428C2 (en) 2002-12-20 2009-09-10 Дзе Маклин Хоспитал Корпорейшн Compounds used for sleep/wakefulness cycle normalisation
US20040266659A1 (en) 2003-06-27 2004-12-30 Stephen LaBerge Substances that enhance recall and lucidity during dreaming
EP1727554A4 (en) 2003-10-08 2009-09-30 Mclean Hospital Corp Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005034874A2 (en) 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
US20090215714A1 (en) 2004-06-10 2009-08-27 Perry Renshaw Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
EP1765075A4 (en) 2004-06-10 2010-11-10 Mclean Hospital Corp Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
US7947661B2 (en) 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
US20100041621A1 (en) 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
US20100041620A1 (en) 2008-08-15 2010-02-18 Perry Renshaw Methods for improving frontal brain bioenergetic metabolism
US20130281410A1 (en) * 2010-05-13 2013-10-24 University Of Utah Research Foundation Methods for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
WO2001068104A1 (en) 2001-09-20
ES2425114T3 (en) 2013-10-11
US20080132472A1 (en) 2008-06-05
US7863254B2 (en) 2011-01-04
EP1274444B1 (en) 2013-05-15
US8575219B2 (en) 2013-11-05
EP1274444A1 (en) 2003-01-15
US8030294B2 (en) 2011-10-04
US20030220291A1 (en) 2003-11-27
US20020019364A1 (en) 2002-02-14
EP1274444A4 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
AU2001247474A1 (en) Compounds for the treatment of psychiatric or substance abuse disorders
AU2935200A (en) Compounds for the treatment of obesity
IL209842A0 (en) Compounds for the treatment of metabolic disorders
MXPA03007960A (en) Compounds and methods for the treatment of urogenital disorders.
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
AU2001292480A1 (en) Novel pyridazine compounds for the treatment of diabetes
AU2001272852A1 (en) Composition for the treatment of migraine
AU2000276362A1 (en) Composition for the treatment of diabetes
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU6910600A (en) Methods for the treatment of mental disorders
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU5038299A (en) Process for the biocidal treatment of surfaces
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
AU2001293891A1 (en) New combination for the treatment of asthma
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
EP1461030A4 (en) Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
IL154378A0 (en) Compounds for the treatment of addictive disorders
CZ20011872A3 (en) Isonipecotamides for the treatment of integrin-mediated disorders
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
SI1468686T1 (en) S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders
AU2000272704A1 (en) Use of compounds for the treatment of obesity
AU4475300A (en) Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression
AU2002327697A1 (en) Compounds for the treatment of pain
AU2002351665A1 (en) Agents for treating lesions of the nervous system